Skip to main content
SpringerLink
Log in

Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objectives

To examine the association between use of anti-hypertensive drugs and prostate cancer incidence among 48,389 men in the Cancer Prevention Study II Nutrition Cohort.

Methods

Proportional hazards models were used to calculate rate ratios (RR) for use of Beta-Blockers (BBs), Calcium Channel Blockers (CCBs), and ACE Inhibitors (ACE) and incident prostate cancer in time-dependent analyses.

Results

During follow-up from 1997 to 2005, we identified 3,031 cases of incident prostate cancer. Anti-hypertensive use was associated with slightly decreased risk of all (RR = 0.90, 95% CI 0.83–0.98) and organ-confined low-grade prostate cancer (RR = 0.89, 95% CI 0.81–0.99), but was not statistically significantly associated with aggressive-fatal prostate cancer (RR = 0.93, 95% CI 0.79–1.10). BB and ACE inhibitor treatment was associated with an approximately 10% lower risk for all prostate cancer in models adjusted for age and race. These associations were attenuated and lost statistical significance when adjusted for history of heart disease. No trend with duration of use was detected.

Conclusions

These results do not support the hypothesis that anti-hypertensive medication is strongly associated with risk of prostate cancer. Confounding by concurrent illness may explain inverse associations seen in other studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ (2008) Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 52(5):818–827. doi:10.1161/HYPERTENSIONAHA.108.113357

    Article  PubMed  CAS  Google Scholar 

  2. Moser M, Franklin SS (2007) Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich) 9(5):316–323. doi:10.1111/j.1524-6175.2007.07152.x

    Article  Google Scholar 

  3. Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G et al (2004) Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 58(1):50–56. doi:10.1002/pros.10294

    Article  PubMed  CAS  Google Scholar 

  4. Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ et al (2004) Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 13(2):255–259. doi:10.1158/1055-9965.EPI-03-0093

    Article  PubMed  CAS  Google Scholar 

  5. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11(8):534–542. doi:10.1016/S1047-2797(01)00246-0

    Article  PubMed  CAS  Google Scholar 

  6. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ et al (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92(9):2462–2470. doi:10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L

    Article  PubMed  CAS  Google Scholar 

  7. Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR et al (1993) Incidence of and mortality from cancer in hypertensive patients. BMJ 306(6878):609–611

    Article  PubMed  CAS  Google Scholar 

  8. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium-channel blockers and risk of cancer. Lancet 349(9051):525–528. doi:10.1016/S0140-6736(97)80084-0

    Article  PubMed  CAS  Google Scholar 

  9. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B et al (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358(9281):539–544. doi:10.1016/S0140-6736(01)05704-X

    Article  PubMed  CAS  Google Scholar 

  10. Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK et al (2000) Cancer risk and mortality in users of calcium channel blockers: a cohort study. Cancer 89(1):165–170. doi:10.1002/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G

    Article  PubMed  CAS  Google Scholar 

  11. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR et al (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026):493–497. doi:10.1016/S0140-6736(96)04277-8

    Article  PubMed  CAS  Google Scholar 

  12. Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6):535–541. doi:10.1023/B:CACO.0000036152.58271.5e

    Article  PubMed  Google Scholar 

  13. Vezina RM, Lesko SM, Rosenberg L, Shapiro S (1998) Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 11(12):1420–1425. doi:10.1016/S0895-7061(98)00176-9

    Article  PubMed  CAS  Google Scholar 

  14. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG et al (1998) Calcium channel blockers and the risk of cancer. Jama 279(13):1000–1004. doi:10.1001/jama.279.13.1000

    Article  PubMed  CAS  Google Scholar 

  15. Ahr HJ, Bomhard E, Enzmann H, Karbe E, Mager H, Sander E et al (1998) Calcium channel blockers and the risk of cancer: a preclinical assessment. Cardiovasc Drugs Ther 12(2):157–169. doi:10.1023/A:1007727010076

    Article  PubMed  CAS  Google Scholar 

  16. Sugimoto K, Simard J, Haagensen DE, Labrie F (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J Steroid Biochem Mol Biol 51(3–4):167–174. doi:10.1016/0960-0760(94)90090-6

    Article  PubMed  CAS  Google Scholar 

  17. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98(3):671–679. doi:10.1172/JCI118838

    Article  PubMed  CAS  Google Scholar 

  18. Palm D, Lang K, Niggemann B, TLt Drell, Masur K, Zaenker KS et al (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118(11):2744–2749. doi:10.1002/ijc.21723

    Article  PubMed  CAS  Google Scholar 

  19. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML et al (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort—rationale, study design and baseline characteristics. Cancer 94:2490–2501. doi:10.1002/cncr.101970

    Article  PubMed  Google Scholar 

  20. Garfinkel L (1985) Selection, follow-up, and analysis in the American Cancer Society prospective studies. Natl Cancer Inst Monogr 67:49–52

    PubMed  CAS  Google Scholar 

  21. Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill JL, Thun MJ, Heath CW (1998) Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 147:556–562

    PubMed  CAS  Google Scholar 

  22. Calle EE, Terrell DD (1993) Utility of the national death index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 137:235–241

    PubMed  CAS  Google Scholar 

  23. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352(9123):179–184. doi:10.1016/S0140-6736(98)03228-0

    Article  PubMed  CAS  Google Scholar 

  24. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A (1999) Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 21(5):217–220. doi:10.1023/A:1008741321384

    Article  PubMed  CAS  Google Scholar 

  25. Kehoe R, Wu SY, Leske MC, Chylack LT Jr (1994) Comparing self-reported and physician-reported medical history. Am J Epidemiol 139(8):813–818

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors thank Ms. Christina Newton for her assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Epidemiology and Surveillance Research, American Cancer Society, 250 Williams Street, Atlanta, GA, 30303, USA

    Carmen Rodriguez, Eric J. Jacobs, Anusila Deka, Alpa V. Patel, Elizabeth B. Bain, Michael J. Thun & Eugenia E. Calle

Authors
  1. Carmen Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric J. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anusila Deka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alpa V. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elizabeth B. Bain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael J. Thun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eugenia E. Calle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. Jacobs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodriguez, C., Jacobs, E.J., Deka, A. et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 20, 671–679 (2009). https://doi.org/10.1007/s10552-008-9280-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-008-9280-0

Keywords

Search

Navigation